Prognosis related to metastatic burden measured by18F- fluorocholine PET/CT in castration-resistant prostate cancer

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 905-910

  Kwee, Sandi A ^a,c   Lim, John ^a,b   Watanabe, Alex ^a   Kromer Baker, Kathleen ^a   Coel, Marc N ^a,b  

^a QUEEN S MEDICAL CENTER   (United States)

^b Hamamatsu/Queen's PET Imaging Center   (United States)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

Castrate resistant prostate cancer; Fluorocholine; Positron emission tomography; Survival

Indexed keywords

FLUOROCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; FLUOROCHOLINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME; WHOLE BODY CT; WHOLE BODY PET; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL; VERY ELDERLY; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; WHOLE BODY IMAGING;

EID: 84903190115     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.135194     Document Type: Article

References (29)

1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30:195-200.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520. (Pubitemid 39315318)
4. Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol). 2013;25:406-430.
5. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
6. Bubley GJ, Carducci M, DahutW, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467. (Pubitemid 29517916)
7. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972-3982.
8. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237. (Pubitemid 46606398)
9. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15:45-55.
10. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273-280.
11. 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106-117.
12. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
13. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506-1513.
14. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290-301.
15. 18F]fluoroalkane sulfonates and fluoroalkylation agents [abstract]. J Labelled Comp Radiopharm. 2003;46(suppl):S46.
16. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948-957. (Pubitemid 29109328)
17. Berruti A, Tucci M, Mosca A, et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer. 2005;93:633-638. (Pubitemid 41486453)
18. Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol. 2012;62:78-84.
19. 18F]fluorothymidine positron emission tomography. Nucl Med Commun. 2011;32:997-1004.
20. Ramírez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296:580-583.
21. Jiménez B, del Peso L, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 andMAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem. 1995;57:141-149.
22. Yalcin A, Clem B, Makoni S, et al. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene. 2010;29:139-149.
23. 11C-choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness. Radiol Oncol. 2012;46:179-188.
24. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm. 2006;3:496-506. (Pubitemid 44639126)
25. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT-comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278-286.
26. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559-566.
27. Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008;112:2393-2400.
28. Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2009;12:241-246.
29. 18F-fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging. 2011;38:14-22.